TKNO Quote, Financials, Valuation and Earnings

Nephros, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of 7.07%. Alpha Teknova, Inc.'s return on equity of -22.95% beat Nephros, Inc.'s return on equity of 16.22%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 114.8%. On the other hand Nephros, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 35.14%. Given that Alpha Teknova, Inc. has higher upside potential than Nephros, Inc., analysts believe Alpha Teknova, Inc. is more attractive than Nephros, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nephros, Inc. has a beta of 1.407, suggesting its more volatile than the S&P 500 by 40.722%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nephros, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Nephros, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are larger than Nephros, Inc. quarterly revenues of $4.8M. Alpha Teknova, Inc.'s net income of -$4.3M is lower than Nephros, Inc.'s net income of $337K. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Nephros, Inc.'s PE ratio is 34.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 5.63x versus 2.89x for Nephros, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Puma Biotechnology, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of 16.24%. Alpha Teknova, Inc.'s return on equity of -22.95% beat Puma Biotechnology, Inc.'s return on equity of 38.49%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 114.8%. On the other hand Puma Biotechnology, Inc. has an analysts' consensus of $3.50 which suggests that it could fall by -42.72%. Given that Alpha Teknova, Inc. has higher upside potential than Puma Biotechnology, Inc., analysts believe Alpha Teknova, Inc. is more attractive than Puma Biotechnology, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Puma Biotechnology, Inc. has a beta of 1.187, suggesting its more volatile than the S&P 500 by 18.747%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Puma Biotechnology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Puma Biotechnology, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are smaller than Puma Biotechnology, Inc. quarterly revenues of $54.5M. Alpha Teknova, Inc.'s net income of -$4.3M is lower than Puma Biotechnology, Inc.'s net income of $8.8M. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Puma Biotechnology, Inc.'s PE ratio is 8.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 5.63x versus 1.44x for Puma Biotechnology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pyxis Oncology, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of -650.85%. Alpha Teknova, Inc.'s return on equity of -22.95% beat Pyxis Oncology, Inc.'s return on equity of -90.91%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 114.8%. On the other hand Pyxis Oncology, Inc. has an analysts' consensus of $7.18 which suggests that it could grow by 307.67%. Given that Pyxis Oncology, Inc. has higher upside potential than Alpha Teknova, Inc., analysts believe Pyxis Oncology, Inc. is more attractive than Alpha Teknova, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Pyxis Oncology, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pyxis Oncology, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Pyxis Oncology, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are larger than Pyxis Oncology, Inc. quarterly revenues of --. Alpha Teknova, Inc.'s net income of -$4.3M is higher than Pyxis Oncology, Inc.'s net income of -$22M. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Pyxis Oncology, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 5.63x versus 38.24x for Pyxis Oncology, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Spero Therapeutics, Inc. has a net margin of -41% compared to Alpha Teknova, Inc.'s net margin of -242.19%. Alpha Teknova, Inc.'s return on equity of -22.95% beat Spero Therapeutics, Inc.'s return on equity of -107.04%.

Alpha Teknova, Inc. has a consensus price target of $10.00, signalling upside risk potential of 114.8%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 56.86%. Given that Alpha Teknova, Inc. has higher upside potential than Spero Therapeutics, Inc., analysts believe Alpha Teknova, Inc. is more attractive than Spero Therapeutics, Inc..

Alpha Teknova, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.062%.

Alpha Teknova, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alpha Teknova, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alpha Teknova, Inc. quarterly revenues are $10.5M, which are larger than Spero Therapeutics, Inc. quarterly revenues of $3M. Alpha Teknova, Inc.'s net income of -$4.3M is higher than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Alpha Teknova, Inc.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alpha Teknova, Inc. is 5.63x versus 4.83x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.